Form 4: Rocket Pharmaceuticals Director Elisabeth Bjork Acquires Stock Options

Director Elisabeth Bjork acquired stock options for Rocket Pharmaceuticals shares on June 13, 2024.

Summary

• Elisabeth Bjork, a director of Rocket Pharmaceuticals, acquired stock options on June 13, 2024.
• She obtained options to purchase 23,944 shares at $22.86, which will vest on June 13, 2025.
• Additionally, she received options for 3,325 shares at $22.86, also vesting on June 13, 2025, in lieu of $50,000 in director retainer fees.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard stock option grant to a director. It indicates confidence but doesn't provide specific financial performance details.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotechnology industry to incentivize performance and align interests with shareholders.
• The vesting schedule of one year is fairly typical for such grants.
• The exercise price is set at the market price on the grant date, which is standard practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates